目的:观察复方斑蝥胶囊与三维适形放疗联合应用对中晚期原发性肝癌的疗效及不良反应.方法:68例中晚期原发性肝癌分为治疗组和对照组,两组放疗方法、剂量相同,治疗组联合应用复方斑蝥胶囊.结果:有效率治疗组79.4%(27/34),对照组58.8%(20/34),P<0.05.治疗后1年、2年生存率治疗组为 73.5%(25/34)和44.1%(15/34),对照组52.9%(18/34)和32.4%(11/34),P<0.05.骨髓抑制发生率治疗组26.5%(9/34),对照组38.2%(13/34),P<0.05.结论:复方斑蝥胶囊与放疗联合应用治疗中晚期原发性肝癌能提高疗效,减轻不良反应.%Objective: To examine the clinical efficacy and side effects of combined application of compound myla-bris capsules and 3 - dimensional conformal radiotherapy ( 3 - DCRT ) in the treatment of primary liver cancer in advanced stages. Methods: A 68 total of patients with advanced primary liver cancer were divided into treatment group and control group. Patients in the two groups were given the same radiotherapy regimen with the same dosage and those in the treatment group additionally administered compound mylabris capsules. Results: The effective rate was79.4% ( 27/34 ) in the treatment group and 58. 8% ( 20/34 ) in the control group ( P <0. 05 ). The 1 - year and 2 - year survival rates were 73. 5% ( 25/34 ), 44. 1% ( 15/34 ) in the treatment group and 52. 9 %( 18/34 ), 32. 4% ( 11/34 ) in the control group ( P < 0. 05 ). Myelosuppression rate was 26. 5% in the treatment group, significantly lower than that in the control group ( P <0. 05 ). Conclusion: Combined application of compound mylabris capsules and 3 - DCRT can increase the clinical efficacy and decrease the side effects
展开▼
